Apollo launch boosts Fujifilm's mammalian expression services

By Dan Stanton contact

- Last updated on GMT

Related tags: Fujifilm diosynth biotechnologies, Biotechnology

Apollo launch boosts Fujifilm's mammalian expression services
Fujifilm has launched a mammalian cell line it says can deliver titers up to 3g/L before subsequent optimisation and will complement its microbial-based platform.

The Apollo platform consists of a CHO DG44-derived host cell line and an expression vector, and will be a complementary offering to Fujifilm Diosynth Biotechnologies’ microbial-based platform, pAVEway, Mark Douglas, Head of Business Development told Biopharma-Reporter.com.

The Apollo platform is specifically designed for the expression of mammalian cell culture biopharmaceuticals,”​ he said, and so for customers the choice of platform is “made dependent on the type of molecule the customer is developing.”

The platform also compromises of optimised media and feed components which allows it to be highly productive – delivering titers of up to 3g/L before subsequent optimisation, the company boasts – as well as speeding up the product lifecycle. Apollo, the firm said, can supply material within 10 weeks of receiving a gene sequence with a manufacturing-ready clonal cell line within 25 weeks.

Douglas told us the platform has been developed between Fujifilm’s facilities in Billingham, UK and North Carolina, US – both of which have seen recent investment in single-use bioreactors​.

However, some steps will only take place at our UK site,” ​he said, “as this is where the initial cell line development is carried out,”​ utilising high-throughput and predictive screen technologies including the firm’s ClonePix shaken fed-batch multi-well plates, and its ambr15 microbioreactor.

Douglas also told us there was a conscious decision to use elements well known and understood by the regulators in developing the platform.

The host is derived from CHO DG44 which is well known and trusted in the biopharmaceutical industry,”​ he said, adding there is “maximum traceability and full characterisation of Fujifilm’s variant of it.”

Related news

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

Discover the world of upstream bioprocessing

Discover the world of upstream bioprocessing

Eppendorf Bioprocess Solutions | 07-Sep-2022 | Technical / White Paper

A must-read for all bioprocess scientists: This bundle of four ebooks created by Eppendorf guides you through the world of upstream bioprocessing.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

The Reagents Behind Much of Molecular Biology

The Reagents Behind Much of Molecular Biology

Thermo Fisher Scientific | 25-Jul-2022 | Case Study

The ability to amplify, modify and fabricate DNA is fundamental to modern molecular biology. Why do so many researchers take their constituent parts for...

Related suppliers

Follow us


View more